home / stock / aqst / aqst news


AQST News and Press, Aquestive Therapeutics Inc. From 10/19/22

Stock Information

Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com

Menu

AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...

AQST - Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET

WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today announced that it will report results for third qu...

AQST - Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction

Aquestive Therapeutics ( NASDAQ: AQST ) said on Tuesday it had received positive feedback from the U.S. Food and Drug Administration for its initial End-of-Phase 2 (EoP2) meeting request to discuss Chemistry, Manufacturing, and Controls for its AQST-109 epinephrine su...

AQST - Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film

FDA’s End-of-Phase 2 written response provides positive feedback related to Chemistry, Manufacturing, and Controls (CMC) to support future NDA filing Supports approach to characterizing Aquestive’s proprietary novel prodrug form of epinephrine API Confirms ...

AQST - Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film

Aquestive Therapeutics ( NASDAQ: AQST ) on Wednesday said it had entered into a licensing and supply agreement for its Libervant buccal film with healthcare company Pharmanovia. AQST's Libervant is a buccally, or inside of the cheek, administered film formulation of diazep...

AQST - Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant(TM) (diazepam) Buccal Film for European and MENA Markets

WARREN, N.J., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives...

AQST - Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Rob Byron / Shutterstock.com Aquestive Therapeutics (NASDAQ: AQST ) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company. Aquestive Therap...

AQST - Aquestive adds 20% as epinephrine sublingual film outperforms autoinjector

Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) gained ~20% pre-market Tuesday after the company announced that its AQST-109 epinephrine sublingual film compared favorably to other forms of epinephrine treatments, including EpiPen® autoinjector of Viatris ( VTRS ). ...

AQST - Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

AQST-109 median time to maximum concentration ( Tmax ) of 12 minutes was faster than EpiPen ® Tmax of 22.5 minutes AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after admi...

AQST - Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

WARREN, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the establishment...

AQST - Aquestive Therapeutics: FDA Stymies Libervant Launch

Summary Shares have lost two-thirds of their value this year. AQST-109 looks like an appealing alternative to Epi-Pen with greater convenience and more consistent, rapid response. Libervant tentative approval by the FDA was disappointing as there's clearly a difference in food...

Previous 10 Next 10